X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (23261) 23261
Newspaper Article (148) 148
Book Chapter (130) 130
Newsletter (104) 104
Magazine Article (41) 41
Publication (9) 9
Book Review (6) 6
Dissertation (6) 6
Conference Proceeding (5) 5
Reference (4) 4
Book / eBook (2) 2
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18657) 18657
male (11061) 11061
female (9243) 9243
platelet aggregation inhibitors - administration & dosage (7550) 7550
middle aged (7004) 7004
platelet aggregation inhibitors - therapeutic use (6987) 6987
aged (6288) 6288
cardiac & cardiovascular systems (4808) 4808
animals (4719) 4719
aspirin (4704) 4704
ticlopidine - analogs & derivatives (4342) 4342
treatment outcome (4301) 4301
clopidogrel (4013) 4013
platelet aggregation inhibitors - adverse effects (3849) 3849
platelet aggregation - drug effects (3640) 3640
risk factors (3609) 3609
adult (3446) 3446
aspirin - administration & dosage (3394) 3394
hematology (3195) 3195
platelet aggregation inhibitors - pharmacology (3099) 3099
peripheral vascular disease (3096) 3096
thrombosis (2983) 2983
blood platelets (2944) 2944
pharmacology & pharmacy (2736) 2736
drug therapy, combination (2720) 2720
time factors (2711) 2711
aspirin - therapeutic use (2608) 2608
ticlopidine - administration & dosage (2430) 2430
platelets (2423) 2423
percutaneous coronary intervention (2371) 2371
blood platelets - drug effects (2256) 2256
ticlopidine - therapeutic use (2041) 2041
aggregation (1959) 1959
abridged index medicus (1916) 1916
stents (1914) 1914
dose-response relationship, drug (1895) 1895
care and treatment (1810) 1810
risk (1800) 1800
drug therapy (1763) 1763
aged, 80 and over (1734) 1734
prospective studies (1717) 1717
platelet aggregation (1709) 1709
stroke (1697) 1697
acute coronary syndromes (1683) 1683
therapy (1654) 1654
surgery (1629) 1629
antiplatelet therapy (1624) 1624
prevention (1585) 1585
mortality (1584) 1584
heart attacks (1582) 1582
cardiology (1571) 1571
myocardial-infarction (1568) 1568
medicine, general & internal (1563) 1563
anticoagulants - therapeutic use (1551) 1551
analysis (1518) 1518
anticoagulants (1481) 1481
blood platelets - metabolism (1478) 1478
rats (1467) 1467
anticoagulants - administration & dosage (1452) 1452
cardiovascular (1449) 1449
hemorrhage - chemically induced (1446) 1446
medicine & public health (1437) 1437
administration, oral (1425) 1425
aspirin - adverse effects (1421) 1421
inhibition (1382) 1382
retrospective studies (1380) 1380
follow-up studies (1347) 1347
research (1346) 1346
cardiovascular disease (1340) 1340
dosage and administration (1301) 1301
ticlopidine - adverse effects (1293) 1293
platelet glycoprotein gpiib-iiia complex - antagonists & inhibitors (1288) 1288
coronary heart disease (1227) 1227
risk assessment (1221) 1221
drug administration schedule (1206) 1206
health aspects (1202) 1202
cardiac patients (1200) 1200
mice (1161) 1161
thrombosis - prevention & control (1152) 1152
angioplasty, balloon, coronary (1128) 1128
activation (1109) 1109
cardiovascular diseases (1104) 1104
myocardial infarction - drug therapy (1080) 1080
anticoagulants - adverse effects (1037) 1037
double-blind method (1024) 1024
patients (1014) 1014
angioplasty (1004) 1004
acute myocardial-infarction (999) 999
disease (997) 997
drug-eluting stents (989) 989
randomized controlled trials as topic (982) 982
aspirin - pharmacology (974) 974
acute coronary syndrome - drug therapy (955) 955
fibrinolytic agents - therapeutic use (951) 951
platelet-aggregation (948) 948
inflammation (936) 936
trial (927) 927
platelet activation - drug effects (922) 922
myocardial infarction (916) 916
internal medicine (904) 904
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (22624) 22624
German (408) 408
Japanese (308) 308
Russian (196) 196
French (180) 180
Spanish (121) 121
Italian (92) 92
Chinese (58) 58
Polish (57) 57
Portuguese (38) 38
Danish (31) 31
Swedish (25) 25
Dutch (24) 24
Hungarian (24) 24
Turkish (21) 21
Norwegian (20) 20
Czech (17) 17
Ukrainian (7) 7
Lithuanian (6) 6
Serbian (6) 6
Hebrew (5) 5
Korean (4) 4
Slovak (3) 3
Croatian (2) 2
Icelandic (2) 2
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 13, pp. 1211 - 1222
Journal Article
by Anand, Sonia S and Bosch, Jackie and Eikelboom, John W and Connolly, Stuart J and Aboyans, Victor and Alings, Marco and Kakkar, Ajay K and Lewis, Basil S and Störk, Stefan and Zhu, Jun and Lopez-Jaramillo, Patricio and O'Donnell, Martin and Commerford, Patrick J and Vinereanu, Dragos and Ryden, Lars and Misselwitz, Frank and Varigos, John D and Vanassche, Thomas and Chen, Edmond and Branch, Kelley and Leong, Darryl P and Bangdiwala, Shrikant I and Hart, Robert G and Yusuf, Salim and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and VOGEL, DANIEL and HRABAR, ADRIAN and CUNEO, CARLOS and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and CARDONA, MARCELO and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and ABRANTES, JOSE ANTONIO and MANENTI, EULER and MAIA, LILIA and HERNANDES, MAURO and ROSSI DOS SANTOS, FABIO and ZIMMERMANN, SERGIO LUIZ and ABIB JR, EDUARDO and LEAES, PAULO and BOTELHO, ROBERTO and BRAILE, MARIA and IZUKAWA, NILO and TANAJURA, LUIZ FERNANDO and SERRANO JUNIOR, CARLOS VICENTE and NASI, LUIZ ANTONIO and TYTUS, RICHARD and PANDEY, SHEKHAR and LONN, EVA and CHA, JAMES and BABAPULLE, MOHAN and LAMY, ANDRE and KIAII, BOB and BHARGAVA, RAKESH and MEHTA, PRAVINSAGAR and HILL, LAURIE and FELL, DAVID and LAM, ANDY and AL-QOOFI, FAISAL and PETRELLA, ROBERT and GLANZ, ANTHONY and NOISEUX, NICOLAS and MERALI, FATIMA and ... and COMPASS Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet (British edition), ISSN 0140-6736, 2018, Volume 391, Issue 10117, pp. 219 - 229
...) inhibitors, and antiplatelet agents (aspirin or a P2Y12 inhibitor) are used to reduce vascular complications.4-6 
MORTALITY | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | THERAPY | OUTPATIENTS | CARDIOVASCULAR EVENT RATES | PREVENTION | RISK | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Carotid Artery Diseases - complications | Male | Peripheral Arterial Disease - complications | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Lower Extremity - surgery | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Rivaroxaban - therapeutic use | Carotid Artery Diseases - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Peripheral Arterial Disease - drug therapy | Carotid Artery Diseases - epidemiology | Morbidity | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Peripheral Arterial Disease - epidemiology | Factor Xa Inhibitors - adverse effects | Aged | Myocardial Infarction - prevention & control | Amputation - statistics & numerical data | Hemorrhage - chemically induced | Lower Extremity - blood supply | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Heart attacks | Medical imaging | Mortality | Clinical trials | Cardiovascular disease | Patients | Disease control | Evidence-based medicine | Carotid arteries | Disease prevention | Coronary vessels | Blood pressure | Carotid artery | Acute coronary syndromes | Thromboembolism | Health risk assessment | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Amputation | Drug | drug therapy | chemically induced | complications | prevention & control | Peripheral Arterial Disease | etiology | Clinical Medicine | Myocardial Infarction | statistics & numerical data | blood supply | Carotid Artery Diseases | Platelet Aggregation Inhibitors | adverse effects | mortality | Lower Extremity | Dose-Response Relationship | therapeutic use | surgery
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
In this large clinical trial, aspirin plus extended-release dipyridamole was found to have an efficacy similar to that of clopidogrel in the prevention of... 
ACTIVE CONTROLLED-TRIALS | HIGH-RISK PATIENTS | TICLOPIDINE | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | ARTERIAL ORIGIN ESPRIT | CEREBRAL-ISCHEMIA | UMCG Approved | NON-INFERIORITY TRIALS | ISSUES | MEDICINE, GENERAL & INTERNAL | PLACEBO | DESIGN | WARFARIN | REGIMENS | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
...‐mg/day maintenance dose) and the proton‐pump inhibitor (PPI) omeprazole (80 mg) when they are administered simultaneously (study 1... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 12/2010, Volume 122, Issue 24, pp. 2619 - 2633
proton pump inhibitors | antiplatelet drugs | gastrointestinal hemorrhage | platelet aggregation inhibitors | aspirin | thienopyridine | AHA Scientific Statements | CYTOCHROME-P450 | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | ACID SUPPRESSION | PERCUTANEOUS CORONARY INTERVENTION | CLOPIDOGREL | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DISEASE | PERIPHERAL VASCULAR DISEASE | PRASUGREL | PEPTIC-ULCERS | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 25, pp. 2423 - 2434
... – 3 Dual antiplatelet therapy (DAPT) with a P2Y 12 inhibitor and aspirin is superior to oral anticoagulation with a vitamin K antagonist in reducing the risk of thrombosis in patients undergoing placement of a first-generation stent, 4... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | THERAPY | RIVAROXABAN | OPEN-LABEL | ANTITHROMBOTIC STRATEGIES | ANTICOAGULATION | Confidence Intervals | Humans | Middle Aged | Male | Hemorrhage - prevention & control | Rivaroxaban - administration & dosage | Factor Xa Inhibitors - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Vitamin K - antagonists & inhibitors | Rivaroxaban - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Stents | Purinergic P2Y Receptor Antagonists - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Kaplan-Meier Estimate | Factor Xa Inhibitors - adverse effects | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Prevention | Complications and side effects | Angiography | Atrial fibrillation | Hemorrhage | Patients | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Angioplasty | Coagulation | Thrombosis | Thrombolysis | Bleeding | Fibrillation | Implants | Vitamin K
Journal Article
The American journal of gastroenterology, ISSN 0002-9270, 12/2010, Volume 105, Issue 12, pp. 2533 - 2549
... of proton pump inhibitors and thienopyridines: a focused update of the ACCF ACG AHA 2008 expert consensus document on reducing the gastrointestinal risks... 
proton pump inhibitors | aspirin | ACCF Expert Consensus Document antiplatelet drugs | gastrointestinal hemorrhage | thienopyridine | platelet aggregation inhibitors | CYTOCHROME-P450 | MYOCARDIAL-INFARCTION | ACID SUPPRESSION | PERCUTANEOUS CORONARY INTERVENTION | CLOPIDOGREL | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DISEASE | PRASUGREL | GASTROENTEROLOGY & HEPATOLOGY | PEPTIC-ULCERS | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2013, Volume 61, Issue 8, pp. 872 - 879
... in CYP2C19 ( 8 ) and/or PON1 ( 5 ), drug–drug interactions (e.g., proton pump inhibitors [PPIs] [ 11,12 ] statins), and intrinsic variation in platelet function... 
Cardiovascular | Internal Medicine | pharmacokinetics | risk factors | receptors | drugs | platelets | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFICACY | GENOTYPE | REACTIVITY | TRIAL | CIGARETTE-SMOKING | PARAOXONASE-1 | RESISTANCE | PRASUGREL | ABSORPTION | ASSOCIATION | Area Under Curve | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Aryl Hydrocarbon Hydroxylases - genetics | Male | Drug Monitoring - methods | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - blood | Ticlopidine - administration & dosage | Adult | Female | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Drug Therapy, Combination | Platelet Aggregation - genetics | Cardiovascular Diseases - etiology | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics | Platelet Function Tests - methods | Aryldialkylphosphatase - genetics | Ticlopidine - analogs & derivatives | Polymorphism, Genetic | Cross-Over Studies | Smoking - metabolism | Confounding Factors (Epidemiology) | Proton Pump Inhibitors - pharmacokinetics | Blood Coagulation - drug effects | ATP-Binding Cassette, Sub-Family B, Member 1 - genetics | Cytochrome P-450 CYP2C19 | ATP Binding Cassette Transporter, Sub-Family B | Cardiovascular Diseases - psychology | Patient Compliance | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Phosphates | Drugs | Prescribing | Medical colleges | Continuing medical education | Metabolites | Vasodilators | Cytochrome P-450 | Physiological aspects | Proton pump inhibitors | Genetic aspects | Patient compliance | Research institutes | Studies | Cytochrome | Body mass index | Nutrition research | Genotype & phenotype | Demographics | Drug therapy | Acute coronary syndromes | Drug dosages
Journal Article